[{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Agreement","leadProduct":"SPC-15","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"5","companyTruncated":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Partnership","leadProduct":"Lecanemab","moa":"Amyloid-beta A4 protein","graph1":"Neurology","graph2":"Phase III","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Frontage Laboratories, Inc \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Frontage Laboratories, Inc \/ Eisai"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Diosmin","moa":"Aryl hydrocarbon receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"Collagen synthesis","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Suzhou Zelgen Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Donafenib","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"9","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Suzhou Zelgen Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Donafenib","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"9","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Betta Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Icotinib Hydrochloride","moa":"Epidermal growth factor receptor (EGFR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"CAS 1421373-65-0","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Zorifertinib","moa":"Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"7","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2018","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Shijiazhuang Yiling Pharmaceutical Co.,Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"XY0206","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PB-119","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase II","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2014","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Frontage Laboratories, Inc","sponsor":"Mira Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Frontage Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Frontage Laboratories, Inc \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"Tigermed","sponsor":"Shanghai Zhimeng Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ZM-H1505R","moa":"Hepatitis B virus Capsid protein (HBV C)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Hua Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Hua Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dorzagliatin","moa":"Hexokinase type IV","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Jiangsu Wuzhong Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Endostatin","moa":"Prolactin receptor (PRLR)","graph1":"Oncology","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Zhejiang Hisun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ad5-nCoV","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Undisclosed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Zhuhai Trinomab Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TNM002","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Multitude Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AMT-151","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Egg-derived A\/H1N1 Pandemic Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Tigermed \/ Undisclosed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ROMANIA","productType":"Dietary Supplement","year":"2016","type":"Inapplicable","leadProduct":"Endolex Forte","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"FaseMETS","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"HighField Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"HF1K16","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Immorna","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"JCXH-105","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"8","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Immorna","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"JCXH-108","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"ITALY","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Pediafl\u00f9","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ITALY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Physiomanna Baby","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"ITALY","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Sonidor","moa":"Undisclosed","graph1":"Sleep","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TL-001","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VG290131","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"\u039cSmin Plus","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"15","companyTruncated":"Tigermed \/ Tigermed"},{"orgOrder":0,"company":"Tigermed","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"ITALY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Tigermed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tigermed \/ Tigermed","highestDevelopmentStatusID":"1","companyTruncated":"Tigermed \/ Tigermed"}]
Find Clinical Drug Pipeline Developments & Deals by Tigermed
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
